The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis

Behavioural Brain Research

Volumn 218, Issue 1, 2011, Pages 57-63

  Krass, M ^a   Wegener, G ^b   Vasar, E ^a   Volke, V ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antidepressant; L Arginine; Nitric oxide

Indexed keywords

AMFEBUTAMONE; ARGININE; FLUOXETINE; IMIPRAMINE; NITRATE; NITRIC OXIDE; NITRITE; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CYCLOHEXANOLS; DEPRESSION; DISEASE MODELS, ANIMAL; IMIPRAMINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NITRIC OXIDE; SWIMMING;

EID: 78649781306     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.11.027     Document Type: Article

References (37)

1. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
2. Olesen J., Sobscki P., Truelsen T., Sestoft D., Jonsson B. Cost of disorders of the brain in Denmark. Nord J Psychiatry 2008, 62:114-120.
3. Andlin-Sobocki P., Jonsson B., Wittchen H.U., Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005, 12(Suppl. 1):1-27.
4. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122:509-522.
5. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996, 29:2-11.
6. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
7. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 2002, 4:183-194.
8. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
9. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
10. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004, 5:11-25.
11. Tanis K.Q., Newton S.S., Duman R.S. Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development. CNS Neurol Disord Drug Targets 2007, 6:151-160.
12. Esplugues J.V. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002, 135:1079-1095.
13. Jefferys D., Funder J. Nitric oxide modulates retention of immobility in the forced swimming test in rats. Eur J Pharmacol 1996, 295:131-135.
14. da Silva G.D., Matteussi A.S., dos Santos A.R., Calixto J.B., Rodrigues A.L. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 2000, 11:3699-3702.
15. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999, 372:207-213.
16. Petrie R.X., Reid I.C., Stewart C.A. The N-methyl-d-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review. Pharmacol Ther 2000, 87:11-25.
17. Heiberg I.L., Wegener G., Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 2002, 134:479-484.
18. Suzuki E., Yagi G., Nakaki T., Kanba S., Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001, 63:221-224.
19. Suzuki E., Yoshida Y., Shibuya A., Miyaoka H. Nitric oxide involvement in depression during interferon-alpha therapy. Int J Neuropsychopharmacol 2003, 6:415-419.
20. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., Le Melledo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004, 56:129-134.
21. Harkin A., Connor T.J., Walsh M., St J.N., Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003, 44:616-623.
22. Volke V., Wegener G., Bourin M., Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 2003, 140:141-147.
23. Yildiz F., Erden B.F., Ulak G., Utkan T., Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology (Berl) 2000, 149:41-44.
24. Wegener G., Volke V., Harvey B.H., Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003, 959:128-134.
25. Dhir A., Kulkarni S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 2007, 568:177-185.
26. Dhir A., Kulkarni S.K. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:921-925.
27. Almeida R.C., Felisbino C.S., Lopez M.G., Rodrigues A.L., Gabilan N.H. Evidence for the involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav Brain Res 2006, 168:318-322.
28. Brocardo P.S., Budni J., Lobato K.R., Kaster M.P., Rodrigues A.L. Antidepressant-like effect of folic acid: Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur J Pharmacol 2008, 598:37-42.
29. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
30. Schmidt H.W. Determination of nitric oxide via measurement of nitrite and nitrate in culture media. Biochemica 1995, 2:22.
31. Volke V., Soosaar A., Koks S., Bourin M., Mannisto P.T., Vasar E. 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl) 1997, 131:399-405.
32. Petit-Demouliere B., Chenu F., Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 2005, 177:245-255.
33. Kumar A., Garg R., Gaur V., Kumar P. Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. Brain Res 2010, 1311:73-80.
34. Ulak G., Mutlu O., Akar F.Y., Komsuoglu F.I., Tanyeri P., Erden B.F. Neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole augment the effects of antidepressants acting via serotonergic system in the forced swimming test in rats. Pharmacol Biochem Behav 2008, 90:563-568.
35. Crespi F. The selective serotonin reuptake inhibitor fluoxetine reduces striatal in vivo levels of voltammetric nitric oxide (NO): a feature of its antidepressant activity?. Neurosci Lett 2010, 470:95-99.
36. Krass M., Runkorg K., Wegener G., Volke V. Nitric oxide is involved in the regulation of marble-burying behavior. Neurosci Lett 2010, 480:55-58.
37. Wegener G., Volke V Nitric oxide synthase inhibitors as antidepressants. Pharmaceuticals 2010, 3(1):273-299.